PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32103983-0	2020	LncRNA DANCR Promotes Sorafenib Resistance via Activation of IL-6/STAT3 Signaling in Hepatocellular Carcinoma Cells.	Sorafenib	22-31	differentiation antagonizing non-protein coding RNA	Homo sapiens	7-12	
32103983-6	2020	DANCR overexpression and knockdown models were established and utilized to investigate the functional role of DANCR on sorafenib resistance in HCC cells.	Sorafenib	119-128	differentiation antagonizing non-protein coding RNA	Homo sapiens	110-115	
32103983-10	2020	Overexpression and knockdown experiments demonstrated that DANCR promoted sorafenib resistance in HCC cells in vitro and in vivo.	Sorafenib	74-83	differentiation antagonizing non-protein coding RNA	Homo sapiens	59-64	
32103983-15	2020	Conclusion: Collectively, our study is the first to elucidate the mechanism of DANCR-mediated sorafenib resistance via PSMD10-IL-6/STAT3 signaling axis, which provides a promising target for developing new therapeutic strategy for sorafenib tolerance of HCC.	Sorafenib	94-103	differentiation antagonizing non-protein coding RNA	Homo sapiens	79-84	
32103983-15	2020	Conclusion: Collectively, our study is the first to elucidate the mechanism of DANCR-mediated sorafenib resistance via PSMD10-IL-6/STAT3 signaling axis, which provides a promising target for developing new therapeutic strategy for sorafenib tolerance of HCC.	Sorafenib	231-240	differentiation antagonizing non-protein coding RNA	Homo sapiens	79-84